Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
about
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized studyPharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.Emergency Hospital Care for Exacerbation of COPD: Is Inhaled Maintenance Therapy Modified?A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.Umeclidinium for the treatment of chronic obstructive pulmonary disease.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapyEfficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.
P2860
Q30620671-7DBD78EF-F5C0-4FBE-AA9C-0437D8261B63Q34787196-92F8DA95-EE49-4F1A-AAA3-A008722165C4Q35224900-22D920B7-1CD8-47D0-8697-A26A342532ABQ36388517-F05854A7-EF3F-4F9D-9E6C-A5AB1A3747D8Q36652471-8E27D424-F2A1-496D-AA6A-72E6E48072A3Q36787818-302F918B-8AC8-4D8A-B8A8-287BB7AFC4D5Q38218619-0F911FC9-1328-48D3-8166-C491A2AB7C00Q38258030-AF4DB3DF-A4A9-4739-975E-E82650529E22Q38259862-DCD24E6A-7351-488A-8B49-404BA99E9FA3Q38266325-E56C8064-D7B3-4BAA-B62A-B7D22E754257Q38692883-90337FBF-60CC-4EB0-99BB-E752720EEDEDQ38717900-ECFE80D6-89D3-4B04-A6A6-A49A914B6158Q39003291-8624A054-7FAB-4689-9246-C70D36A81F0FQ40449015-870DFDD4-3F46-427F-A890-DFBDD8049FABQ40737609-E64A5CFF-5D09-46C4-9A82-67FAADE38E69
P2860
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dose response of umeclidinium ...... a randomised cross-over study.
@ast
Dose response of umeclidinium ...... a randomised cross-over study.
@en
type
label
Dose response of umeclidinium ...... a randomised cross-over study.
@ast
Dose response of umeclidinium ...... a randomised cross-over study.
@en
prefLabel
Dose response of umeclidinium ...... a randomised cross-over study.
@ast
Dose response of umeclidinium ...... a randomised cross-over study.
@en
P2093
P2860
P356
P1476
Dose response of umeclidinium ...... a randomised cross-over study.
@en
P2093
Alison Church
Jean Brooks
Misba Beerahee
Palvi Shah
Rashmi Mehta
P2860
P2888
P356
10.1186/1471-2466-14-2
P577
2014-01-06T00:00:00Z
P5875
P6179
1036560395